Genmab
GMAB
289 hedge funds and large institutions have $2.81B invested in Genmab in 2026 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 101 increasing their positions, 99 reducing their positions, and 30 closing their positions.
2,167% more call options, than puts
Call options by funds: $146M | Put options by funds: $6.45M
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
67% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 30
26% more capital invested
Capital invested by funds: $2.23B → $2.81B (+$572M)
5% more funds holding
Funds holding: 274 → 289 (+15)
3.67% more ownership
Funds ownership: 12.74% → 16.4% (+3.7%)
2% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 99
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$137M |
| 2 |
DM
Deerfield Management
New York
|
+$117M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$87.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$65.8M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$52.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
-$41.4M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$24.2M |
| 3 |
Renaissance Technologies
New York
|
-$23.8M |
| 4 |
Morgan Stanley
New York
|
-$14.7M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.57M |
GMAB Hedge Fund Activity: Q2 2026 in Review
289 of the 8,296 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q2 2026, worth a combined $2.81B — up 26% from $2.23B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new GMAB positions and 30 closed out — a net gain of 20 holders — while 101 added to existing stakes and 99 trimmed.
The largest buyer was Paradigm Biocapital Advisors, adding an estimated $137M. The largest seller was Orbis Allan Gray, cutting an estimated $41.4M.
- 289 institutional investors held Genmab (GMAB) as of Q2 2026, up from 274 in Q1 2026.
- Funds reported $2.81B of Genmab stock for Q2 2026, up 26% quarter-over-quarter.
- 50 funds opened new Genmab positions in Q2 2026 and 30 closed out, a net change of +20 holders.
- The largest Genmab buyer in Q2 2026 was Paradigm Biocapital Advisors, an estimated $137M added.
- The largest Genmab seller in Q2 2026 was Orbis Allan Gray, an estimated $41.4M sold.
Based on aggregated 13F filings for Q2 2026.